News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Exelixis (EXEL)-Discovered Compounds To Be Featured In 10 Presentations At ESMO 2017 Congress

8/1/2017 6:26:29 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

- CABOSUN overall survival results and independent radiology review committee analysis of progression-free survival data to be presented during poster discussion session on September 10 -

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced that data from clinical trials of cabozantinib and cobimetinib will be the subject of 10 presentations at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, September 8 – 12, 2017.

Progression-free survival by independent radiology review and updated overall survival results from CABOSUN, a randomized phase 2 clinical trial of cabozantinib compared with sunitinib in patients with previously untreated advanced renal cell carcinoma (RCC), will be presented as a late-breaking abstract in the Genitourinary Tumours, Non-Prostate poster discussion session on Sunday, September 10. Final data from the phase 1 study of cabozantinib in combination with nivolumab with or without ipilimumab for the treatment of metastatic urothelial carcinoma and other genitourinary malignancies will be presented in the Genitourinary Tumours, Non-Prostate oral presentation session on Saturday, September 9. Additionally, poster presentations will detail the evaluation of cabozantinib in RCC and advanced penile squamous cell carcinoma, and of cobimetinib in combination studies in metastatic melanoma.

We look forward to this year’s ESMO Congress where new data from the CABOSUN trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma will be presented, as well as the final analysis from the study exploring cabozantinib in combination with nivolumab and ipilimumab in genitourinary tumors, including metastatic urothelial carcinoma,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis. “The slate of data featuring Exelixis-discovered compounds demonstrates our commitment to advancing our ongoing clinical research program to help improve care and outcomes for patients with cancer.”

Cabozantinib to be featured in eight presentations

The full schedule of cabozantinib presentations expected at the meeting is as follows:

Oral Presentation

[846O] “Final results of a phase I study of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus Ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies”
Dr. Rosa Nadal, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
Session: Genitourinary Tumours, Non-Prostate
Oral presentation Saturday, September 9, 9:15 – 10:45 a.m. CEST, Madrid Auditorium
Note: This is a National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP) study.

Read at

Related News

comments powered by Disqus